These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33065403)

  • 1. Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy.
    Lobo SA; Bączyk P; Wyss B; Widmer JC; Jesus LP; Gomes J; Batista AP; Hartmann S; Wassmann P
    J Pharm Biomed Anal; 2021 Jan; 192():113650. PubMed ID: 33065403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
    Lavoisier A; Schlaeppi JM
    MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical Workflows to Unlock Predictive Power in Biotherapeutic Developability.
    Trikeriotis M; Akbulatov S; Esposito U; Anastasiou A; Leszczyszyn OI
    Pharm Res; 2023 Feb; 40(2):487-500. PubMed ID: 36471025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of colloidal stability of high concentration protein formulations.
    Garidel P; Blume A; Wagner M
    Pharm Dev Technol; 2015 May; 20(3):367-74. PubMed ID: 24392929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developability assessment for monoclonal antibody drug candidates: a case study.
    Garripelli VK; Wu Z; Gupta S
    Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blueprint for antibody biologics developability.
    Mieczkowski C; Zhang X; Lee D; Nguyen K; Lv W; Wang Y; Zhang Y; Way J; Gries JM
    MAbs; 2023; 15(1):2185924. PubMed ID: 36880643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of Antibody CDR Residues to Chemical Modifications Can Be Revealed Prior to Antibody Humanization and Aid in the Lead Selection Process.
    Xu A; Kim HS; Estee S; ViaJar S; Galush WJ; Gill A; Hötzel I; Lazar GA; McDonald P; Andersen N; Spiess C
    Mol Pharm; 2018 Oct; 15(10):4529-4537. PubMed ID: 30118239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early engineering approaches to improve peptide developability and manufacturability.
    Furman JL; Chiu M; Hunter MJ
    AAPS J; 2015 Jan; 17(1):111-20. PubMed ID: 25338742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of antibody self-interaction by bio-layer interferometry as tool to support lead candidate selection during preformulation and developability assessments.
    Domnowski M; Hackner B; Neuber T; Jaehrling J; Frieß W
    Int J Pharm; 2020 Nov; 589():119854. PubMed ID: 32898632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.
    Esfandiary R; Hayes DB; Parupudi A; Casas-Finet J; Bai S; Samra HS; Shah AU; Sathish HA
    J Pharm Sci; 2013 Jan; 102(1):62-72. PubMed ID: 23150484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment.
    Wang T; Kumru OS; Yi L; Wang YJ; Zhang J; Kim JH; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2013 Aug; 102(8):2520-37. PubMed ID: 23824562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of monoclonal antibodies after simulated subcutaneous administration.
    Schuster J; Mahler HC; Joerg S; Kamuju V; Huwyler J; Mathaes R
    J Pharm Sci; 2021 Jun; 110(6):2386-2394. PubMed ID: 33722546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of effects of pH and ionic strength on colloidal stability of IgG solutions by PEG-induced liquid-liquid phase separation.
    Thompson RW; Latypov RF; Wang Y; Lomakin A; Meyer JA; Vunnum S; Benedek GB
    J Chem Phys; 2016 Nov; 145(18):185101. PubMed ID: 27846698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, heterogeneity and developability assessment of therapeutic antibodies.
    Xu Y; Wang D; Mason B; Rossomando T; Li N; Liu D; Cheung JK; Xu W; Raghava S; Katiyar A; Nowak C; Xiang T; Dong DD; Sun J; Beck A; Liu H
    MAbs; 2019; 11(2):239-264. PubMed ID: 30543482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pragmatic mAb lead molecule engineering from a developability perspective.
    Chi B; De Oliveira G; Gallagher T; Mitchell L; Knightley L; Gonzalez CC; Russell S; Germaschewski V; Pearce C; Sellick CA
    Biotechnol Bioeng; 2021 Oct; 118(10):3733-3743. PubMed ID: 33913507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Chemical Space for New Substances to Stabilize a Therapeutic Monoclonal Antibody.
    Tosstorff A; Menzen T; Winter G
    J Pharm Sci; 2020 Jan; 109(1):301-307. PubMed ID: 31697947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Nature of High-Throughput Assays in ADC Formulation Screening.
    Mills BJ; Godamudunage MP; Ren S; Laha M
    J Pharm Sci; 2023 Jul; 112(7):1821-1831. PubMed ID: 37037342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.